Remus Pharma.

Remus Pharmaceuticals reported robust consolidated financial results for FY25, with revenues reaching INR 620.36 crores, a significant 191% increase year-on-year. This substantial growth was primarily attributed to the full consolidation of its US subsidiary, which was only partially consolidated in the previous period. Consolidated EBITDA for FY25 stood at Rs. 50.67 crores, up 59% year-on-year, while net profit allocated to Remus was INR 29.07 crores. For H2 FY25, consolidated revenues were Rs. 347.75 crores, an 88% increase year-on-year, and EBITDA grew 29% to Rs. 27.15 crores. The company noted that the US subsidiary's high-volume, low-margin business model led to a proportionally lower bottom-line growth compared to the top-line.

Remus continues to expand its global footprint, operating in over 40 countries for pharmaceutical finished formulations, with a strong presence in Latin America. The company emphasizes its ability to enter markets rapidly with new products, leveraging its R&D and regulatory expertise. Over 95% of its exports are advanced and niche formulations, including tablets, capsules, injections, inhalers, soft gels, and oral suspensions, ensuring high-quality care globally. The company operates through a robust network of B2B, B2C, and institutional partnerships.

In H2 FY25, Remus made significant strides in entering new markets and registering new products. It successfully commercialized over 10 off-patent pharmaceutical products, adding to its global portfolio. The company also filed 170 new trademarks and product registrations, with 35 already secured and approved, further expanding its brand presence. Regulatory progress includes initiating product registrations in new countries such as Bosnia, Kosovo, Mexico, Tanzania, and Mauritius, alongside launching its own brands and marketing in key Latin American markets like Chile and Peru.

A key strategic focus for Remus is the expansion of its B2C business model, which currently accounts for 10-15% of its operations. The company aims to increase this to 25-30% by the end of FY25, anticipating significant gross margin improvements in the coming years due to the higher margins associated with B2C sales and branded generics. This shift is expected to drive margin expansion as more products are launched under their own branding, reducing reliance on typical generics that face greater price erosion.

Remus maintains an R&D spend of 2-3% of its turnover, which is crucial for product registration and development across multiple regions and countries. This R&D investment supports the company's ability to introduce new products that meet local health ministry approvals. The company has developed and commenced filing for new molecules, including semaglutide-like products (Mounjaro, Rybelsus), targeting the weight loss category. Commercialization of these products in markets without patent issues is aimed for H2 FY26, promising new revenue streams.

The company announced plans to establish a branch office in Singapore, replacing an earlier decision to open an office in Dubai. This move is strategic, as Singapore offers significant flexibility for international business operations. The Singapore branch will serve as an offshore arm, enhancing the feasibility and efficiency of conducting global business for Remus Pharmaceuticals.